CliffBio
small molecule

TRILIPIX

CHOLINE FENOFIBRATE

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameTRILIPIX
Active ingredientCHOLINE FENOFIBRATE
StrengthEQ 135MG FENOFIBRIC ACID **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formCAPSULE, DELAYED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2008
Marketing statusDISCN

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

TRILIPIX patent cliff — loss of exclusivity — | CliffBio